Current Report Filing (8-k)
August 26 2022 - 4:39PM
Edgar (US Regulatory)
0001860657
false
0001860657
2022-08-23
2022-08-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August
23, 2022
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in our charter)
Delaware |
|
001-41160 |
|
87-2147982 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
210 Broadway, Suite 201
Cambridge, MA |
|
02139 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(401) 426-4664
(Registrant’s telephone number, including area
code)
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
ALLR |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing.
On August 23, 2022, Allarity Therapeutics,
Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”)
stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022 (the
“Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) which requires listed companies to
timely file all periodic financial reports with the Securities and Exchange Commission.
The Notice states that the Company
has sixty (60) calendar days from August 23, 2022, or until October 24, 2022, to regain compliance by filing its Form 10-Q or to submit
to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules.
The Company intends to file its
Form 10-Q as soon as practicable. If the Company is unable to file its Form 10-Q by October 24, 2022, the Company intends to submit a
plan to regain compliance with Nasdaq. If Nasdaq accepts the Company’s plan, then Nasdaq may, in its discretion, grant the Company
up to 180 days from the prescribed due date for filing the Form 10-Q, or until February 20, 2023, to regain compliance. If Nasdaq does
not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The
Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.
Item 7.01 Regulation FD Disclosure.
On August
26, 2022, the Company issued a press release disclosing its receipt of the Notice referenced above. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This
information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate
it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. By furnishing this information
on this Current Report on Form 8-K, we make no admission as to the materiality of any information in this report that is required to be
disclosed solely by reason of Regulation FD.
Item 9.01 Financial Statements
and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto
duly authorized.
|
Allarity Therapeutics, Inc. |
|
|
|
|
|
By: |
/s/ Joan Brown |
|
|
Joan Brown
|
|
|
Chief Financial Officer |
|
|
|
Dated: August 26, 2022 |
|
|
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Apr 2023 to Apr 2024